CARL L GORDON
CIK 1282930 · last filed 2026-01-05
CARL L GORDON is a corporate insider who has filed 105 SEC Form 4 insider transactions across 21 companies since 2010. The most recent filing, for CMPX, was dated Jan 5, 2026. Across all open-market trades the lifetime net is +$29.5M, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $260.7M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$260.72M
21
105
$29.49M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| CMPX | Director | 15,219,994 | $2.04 | $31.05M | $14.98M | 10 | 2026-01-05 |
| KROS | Director | 764,405 | $10.07 | $7.70M | -$5.00M | 8 | 2025-12-18 |
| MBX | Director | 747,887 | $60.06 | $44.92M | $14.02M | 3 | 2025-02-19 |
| NCNA | Director | — | $1.29 | — | $0 | 1 | 2024-08-23 |
| Terns Pharmaceuticals, Inc. (TERN) Delisted | Director | 1,968,480 | $52.95 | $104.23M | $17.44M | 9 | 2024-07-17 |
| ACET | Director | 41,154 | $8.20 | $337.5K | $9.33M | 10 | 2024-06-07 |
| Theseus Pharmaceuticals, Inc. (THRX) Delisted | Director | 0 | $4.06 | $0 | $14.49M | 9 | 2024-02-14 |
| AVBP | Director | 1,513,664 | $29.98 | $45.38M | $8.00M | 1 | 2024-01-31 |
| Kinnate Biopharma Inc. (KNTE) Delisted | Director | 1,368,339 | $2.65 | $3.63M | $24.75M | 9 | 2023-06-13 |
| Disc Medicine, Inc. (GMTX) Delisted | Director | — | $13.50 | — | $0 | 1 | 2021-10-06 |
| ORIC | Director | 2,212,571 | $11.91 | $26.35M | -$10.67M | 8 | 2021-06-17 |
| Prevail Therapeutics Inc. (PRVL) Delisted | Director | 13,822,463 | — | — | $15.00M | 2 | 2020-06-19 |
| Turning Point Therapeutics, Inc. (TPTX) Delisted | Director | 2,027,550 | $76.01 | $154.11M | $6.48M | 2 | 2020-06-17 |
| ALEC | Director | 94,075 | $1.52 | $143.0K | $7.82M | 2 | 2019-05-14 |
| ARMO BioSciences, Inc. (ARMO) Delisted | Director | 0 | — | — | $0 | 3 | 2018-06-22 |
| X4 Pharmaceuticals, Inc (ASNS) Delisted | Director | 3,115 | $0.08 | $243 | $5.00M | 4 | 2018-06-07 |
| NTLA | Director | 2,662,180 | $10.89 | $28.99M | $4.50M | 3 | 2017-05-19 |
| Cartesian Therapeutics, Inc. (SELB) Delisted | Director | 12,193 | $0.88 | $10.7K | $7.70M | 1 | 2016-06-29 |
| AMRN | Director | 285 | $13.95 | $4.0K | -$108.10M | 13 | 2012-09-05 |
| PCRX | Director | 2,828,941 | $26.81 | $75.84M | $3.75M | 1 | 2011-02-10 |
| GNOM | Director | — | $53.90 | — | $0 | 1 | 2010-12-02 |
Recent Filings
105 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-01-05 | CMPX | Grant (A) | — | $0 | EDGAR |
| 2025-12-18 | KROS | Disp (D) | −214,522 | -$3.81M | EDGAR |
| 2025-06-06 | KROS | Grant (A) | +5,250 | $0 | EDGAR |
| 2025-04-11 | CMPX | Sell (S) | −3,571,428 | -$5.68M | EDGAR |
| 2025-02-19 | MBX | Buy (P) | +190,672 | $2.02M | EDGAR |
| 2025-02-13 | CMPX | Grant (A) | — | $0 | EDGAR |
| 2024-11-05 | — | Mixed | +2,677,256 | $10.00M | |
| 2024-09-17 | MBX | Mixed | +3,812,215 | $12.00M | EDGAR |
| 2024-09-13 | MBX | Grant (A) | — | $0 | EDGAR |
| 2024-08-23 | NCNA | Mixed | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.